Sylvester’s C. Ola Landgren: “I was convinced that this is really the way to go”
Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study published in the April issue of Clinical Lymphoma, Myeloma, and Leukemia.
Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.
The phase I/II LINKER-MM1 trial of linvoseltamab in R/R MM produced positive pivotal data in patients with relapsed/refractory multiple myeloma.
FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).
Royal College of Surgeons in Ireland preclinical research found that venetoclax, a medication currently approved for leukemia, may have benefits for patients with multiple myeloma when used in combination with another drug—a demethylase inhibitor called 5-azacytidine. This discovery offers a new avenue of treatment options for the currently incurable disease.
FDA granted HDP-101 orphan drug designation in multiple myeloma.
Sometimes in oncology, you get “beat-the-reaper” stories.
An interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma, showed that the trial met its primary endpoint of progression-free survival at a prespecified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.
FDA approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the first FDA-approved denosumab biosimilars, to treat all indications of the reference medicines.
